Business context and reporting period
Entity discrepancy: The supplied filing is Petra Acquisition Inc.’s Form 10-K, not a filing for Revelation Biosciences, Inc. This summary reflects Petra’s filing. It covers the year ended December 31, 2020; the company filed on March 31, 2021.
Petra was a blank-check company formed to pursue a business combination, with an intended focus on healthcare or healthcare-related businesses but no industry restriction. It had not identified a target or begun commercial operations by year-end. Its IPO closed in October 2020.
Financial results and position
| Metric | FY 2020 / December 31, 2020 |
|---|---|
| Revenue | None; no operating revenue since inception |
| Net loss | $136,408, or $0.03 per share |
| Operating expenses | $145,492, primarily professional fees and insurance |
| Operating cash flow | $(218,713) |
| Trust account | $73,510,915, principally invested in short-term U.S. Treasury securities; restricted for the business combination and specified redemptions |
| Cash and marketable securities outside trust | $537,021 combined ($11,734 cash and $525,287 marketable securities) |
| Working capital | Approximately $618,000 |
| Total assets / total liabilities | $74,162,206 / $2,945,032 |
| Debt | No long-term debt reported; a $125,000 sponsor note was repaid in October 2020. Deferred underwriting commissions were $2,911,260. |
No meaningful operating-margin comparison is available because Petra had no operating business. Its 2019 inception-period net loss was $3,638, consisting of professional fees; 2020 results reflect formation, public-company costs and trust/investment income.
Material changes versus the prior period
- Petra completed an IPO of 7,000,000 units at $10 each in October 2020 and sold 278,151 additional units through a partial over-allotment exercise, raising total gross public-offering proceeds of approximately $72.8 million.
- The sponsor purchased 3,233,446 private warrants for approximately $3.2 million. The trust account held approximately $73.5 million at year-end.
- The 2019 comparison covers only the period from incorporation on November 20, 2019, through year-end; the company was not yet public then.
Outlook, risks and unusual items
- The company had until October 13, 2021 to complete a business combination. If unsuccessful, it was required to cease operations and redeem public shares, subject to creditor claims and applicable law; warrants would expire worthless.
- Management believed available working capital and borrowing capacity would meet needs through the earlier of a business combination or one year from the filing, but warned that estimates could prove inadequate. Sponsor or insider working-capital loans were optional, not committed.
- Management highlighted risks including COVID-19 disruption, competition for targets, conflicts of interest and limited management time, dilution or debt raised for a transaction, shareholder redemptions, and possible third-party claims against trust funds. The sponsor’s trust-protection indemnity may be difficult to collect.
- Advisors were entitled to a contingent fee equal to 4% of IPO gross proceeds upon completion of a business combination. The filing also reports founder-share cancellations and related-party sponsor financing.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end. The auditor issued an unqualified opinion on the financial statements; it did not audit internal controls.
Most important facts for investors to verify
- Confirm the filing belongs to Petra Acquisition Inc., not Revelation Biosciences, Inc., before using it for company-specific analysis.
- Check any later filings for whether Petra completed a business combination, extended its deadline, or liquidated.
- Reconcile the trust balance, redemption terms, deferred underwriting commission and any claims or withdrawals in subsequent disclosures.
- Review later disclosures for sponsor loans, transaction fees, redemptions, dilution and the status of public and private warrants.